Companies IGM Biosciences
IGM Biosciences (IGMS): executive pay, fiscal 2023
Free brief. Every figure links to the company’s own filing.
IGM Biosciences no longer files a proxy statement; its last pay data is FY2023.
CEO vs. named peers1st pct.Of 5 peer CEOs
CEO pay, last three years
- $5,316,460FY2022
- $3,207,328FY2023
CEO total pay was $3,207,328 in fiscal 2023, down from $5,316,460 in fiscal 2022.
FY2023: salary $646,797 · bonus $0 · stock awards $868,050 · option awards $1,336,743
Executives and directors
Bruce Keyt · Chief Scientific OfficerChris Takimoto · Chief Medical OfficerFred Schwarzer · CEOChristina Teng Topsoe · DirectorElizabeth H.Z. Thompson · Independent DirectorFelix J. Baker · Independent DirectorJakob Haldor Topsoe · DirectorJulie Hambleton · Independent DirectorM. Kathleen Behrens · Independent DirectorMichael Lee · Independent DirectorMichael Loberg · Former director (through FY2023)William Strohl · Independent Director
Frequently asked questions
Who was the highest-paid executive at IGM Biosciences in fiscal 2023?
As disclosed, Fred Schwarzer (Chief Executive Officer, President and Director) was the highest-paid executive at IGM Biosciences in fiscal 2023, with total compensation of $3,207,328.
How does IGM Biosciences's chief executive pay compare to its disclosed peer group?
As disclosed, Fred Schwarzer's total compensation ranked at the 1st percentile of IGM Biosciences's disclosed peer group.
How much does IGM Biosciences spend in total on board compensation for fiscal 2023?
As disclosed, IGM Biosciences reported total board compensation of $271,892 for fiscal 2023.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Fred Schwarzer | $646,797 | $0 | $868,050 | $1,336,743 | $355,738 | $0 | $0 | $3,207,328 |
| Chief Executive Officer, President and Director | ||||||||
| Bruce Keyt | 492,326 | 0 | 337,575 | 519,845 | 221,458 | 0 | 0 | 1,571,204 |
| Chief Scientific Officer | ||||||||
| Chris Takimoto | 486,492 | 0 | 337,575 | 519,845 | 218,900 | 0 | 0 | 1,562,812 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2023 total | FY2022 total | FY2021 total | Δ FY2022→2023 |
|---|---|---|---|---|
| Fred Schwarzer | $3,207,328 | $5,316,460 | — | ↓ −2,109,132 |
| Bruce Keyt | 1,571,204 | 1,839,300 | — | ↓ −268,096 |
| Chris Takimoto | 1,562,812 | 1,827,118 | — | ↓ −264,306 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company aims to ensure that the compensation offered to executive officers is competitive and fair by using a peer group to determine appropriate levels. The compensation committee evaluates total compensation based on company results, individual contributions, and performance toward individual goal achievement.
| CEO STI target (% of salary) | 55% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2023
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Chris Takimoto | OPTION | — | — | — | — | — | $519,845 |
| Fred Schwarzer | RSU | — | — | — | — | — | 868,050 |
| Fred Schwarzer | OPTION | — | — | — | — | — | 1,336,743 |
| Chris Takimoto | RSU | — | — | — | — | — | 337,575 |
| Bruce Keyt | RSU | — | — | — | — | — | 337,575 |
| Bruce Keyt | OPTION | — | — | — | — | — | 519,845 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Chris Takimoto | $337,575 | $0 | $519,845 | 0.0% |
| Fred Schwarzer | 868,050 | 0 | 1,336,743 | 0.0% |
| Bruce Keyt | 337,575 | 0 | 519,845 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2023
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Bruce Keyt | Option | 3,125 | 40.27 | — |
| Fred Schwarzer | Option | 6,250 | 40.27 | — |
| Bruce Keyt | RSU | 9,375 | — | 77,906 |
| Chris Takimoto | RSU | 9,375 | — | 77,906 |
| Bruce Keyt | Option | 14,584 | 91.5 | — |
| Bruce Keyt | RSU | 26,250 | — | 218,138 |
| Chris Takimoto | RSU | 26,250 | — | 218,138 |
| Fred Schwarzer | Option | 36,459 | 91.5 | — |
| Bruce Keyt | Option | 42,188 | 17.11 | — |
| Chris Takimoto | Option | 42,188 | 17.11 | — |
| Bruce Keyt | Option | 42,657 | 12.86 | — |
| Chris Takimoto | Option | 42,657 | 12.86 | — |
| Chris Takimoto | Option | 59,375 | 68.01 | — |
| Fred Schwarzer | RSU | 67,500 | — | 560,925 |
| Fred Schwarzer | Option | 109,688 | 12.86 | — |
| Fred Schwarzer | Option | 196,875 | 17.11 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| William StrohlIndependent · Research and Clinical Development (Co-Chair) | $90,000 | $0 | $146,594 | — | — | $236,594 |
| Julie HambletonIndependent · Audit · Research and Clinical Development (Co-Chair) | 57,500 | 0 | 146,594 | — | — | 204,094 |
| Michael LobergIndependent · Not standing for re-election · Departed during FY | 0 | 35,950 | 146,594 | — | — | 182,544 |
| M. Kathleen BehrensIndependent · Audit (Chair) · Compensation · Nominating/Governance | 0 | 31,704 | 146,594 | — | — | 178,298 |
| Felix J. BakerIndependent · Research and Clinical Development | 0 | 21,955 | 146,594 | — | — | 168,549 |
| Elizabeth H.Z. ThompsonIndependent · Audit · Compensation · Nominating/Governance · Research and Clinical Development | 15,285 | 0 | 152,250 | — | — | 167,535 |
| Michael LeeIndependent | 0 | 19,498 | 146,594 | — | — | 166,092 |
| Fred SchwarzerEmployee director | — | — | — | — | — | 0 |
| Jakob Haldor Topsoe | 0 | — | — | — | — | — |
| Christina Teng Topsoe | 0 | — | — | — | — | — |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2023 |
|---|---|
| Cash retainers and fees | $162,785 |
| Equity awards (grant-date value) | $109,107 |
| All other compensation | $0 |
| Total cost of the board | $271,892 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names IGM Biosciences as a peer
Companies that benchmark against IGMS
14 companies name IGMS as a compensation peer
The list of companies that name IGMS as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2023
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Gilead Sciences | 2025 | Daniel O'Day | $1,795,192 | $15,238,402 | $4,500,060 | $4,848,120 | $28,437,198 |
| 2 | Pfizer | 2025 | Albert Bourla | 1,800,000 | 9,442,705 | 8,998,141 | 5,400,000 | 27,585,301 |
| 3 | Bristol-Myers Squibb | 2025 | Christopher Boerner | 1,586,346 | 16,061,399 | 0 | 3,754,684 | 21,879,919 |
| 4 | Merck & Co. | 2025 | Robert Davis | 1,645,302 | 12,102,838 | 3,380,004 | 2,326,500 | 20,797,845 |
| 5 | IGM Biosciences | 2023 | Fred Schwarzer | 646,797 | 868,050 | 1,336,743 | 355,738 | 3,207,328 |
| — | AstraZeneca | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| IGM Biosciences | not disclosed | not disclosed | not disclosed | Aon |
| AstraZeneca | not disclosed | not disclosed | not disclosed | not disclosed |
| Bristol-Myers Squibb | 157.66% | PSU 60 · MSU 40 | Yes — 3-Year Relative TSR CAGR | Farient Advisors LLC |
| Gilead Sciences | 180% | PSU 50 · Option 25 · RSU 25 | Yes — Relative TSR | FW Cook |
| Merck & Co. | 94% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (R-TSR) | FW Cook |
| Pfizer | 150% | PSU 50 · MSU 50 | Yes — relative TSR as compared to the NYSE Arca Pharmaceutical Index (DRG Index or DRG) | Meridian Compensation Partners, LLC |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2024 | 2024-06-11 | — | — | — | — | — |
| 2023 | 2023-06-23 | — | — | — | — | — |
| 2022 | 2022-06-21 | — | — | — | — | — |
| 2021 | 2021-06-24 | — | — | — | — | — |
| 2020 | 2020-07-30 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2024 | 2024-06-11 | —a |
| 2023 | 2023-06-23 | —b |
| 2022 | 2022-06-21 | —c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2023 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | Director | 2024-12-31 | A | 1,994 | $0 | $0 | Common | Form 4 ↗ |
| Redmile Group, LLC | Director | 2024-12-31 | A | 1,734 | 0 | 0 | Common, indirect | Form 4 ↗ |
| Christina Teng Topsoe | Director | 2024-12-31 | A | 2,687 | 0 | 0 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2024-12-31 | A | 1,994 | 0 | 0 | Common | Form 4 ↗ |
| M. Kathleen Behrens | Director | 2024-12-31 | A | 3,078 | 0 | 0 | Common | Form 4 ↗ |
| Michael Lee | Director | 2024-12-31 | A | 1,734 | 0 | 0 | Common, indirect | Form 4 ↗ |
| Jakob Haldor Topsoe | Director | 2024-12-31 | A | 1,734 | 0 | 0 | Common | Form 4 ↗ |
| Elizabeth H.Z. Thompson | Director | 2024-12-31 | A | 1,452 | 0 | 0 | Common | Form 4 ↗ |
| Steven Weber | Principal Accounting Officer | 2025-01-15 | D | 1,122 | 2 | 1,907 | Common, open-market sale | Form 4 ↗ |
| Misbah Tahir | Chief Financial Officer | 2025-03-14 | D | 7,329 | 1 | 9,015 | Common, open-market sale | Form 4 ↗ |
| Lisa Lynn Decker | Chief Business Officer | 2025-03-14 | D | 4,512 | 1 | 5,550 | Common, open-market sale | Form 4 ↗ |
| Mary Beth Harler | Director | 2025-03-14 | D | 7,329 | 1 | 9,015 | Common, open-market sale | Form 4 ↗ |
| Steven Weber | Principal Accounting Officer | 2025-03-14 | D | 1,701 | 1 | 2,092 | Common, open-market sale | Form 4 ↗ |
| Christina Teng Topsoe | Director | 2025-03-31 | A | 1,284 | 0 | 0 | Common | Form 4 ↗ |
| Jakob Haldor Topsoe | Director | 2025-03-31 | A | 828 | 0 | 0 | Common | Form 4 ↗ |
| Elizabeth H.Z. Thompson | Director | 2025-03-31 | A | 694 | 0 | 0 | Common | Form 4 ↗ |
| Michael Lee | Director | 2025-03-31 | A | 828 | 0 | 0 | Common, indirect | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2025-03-31 | A | 953 | 0 | 0 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2025-03-31 | A | 953 | 0 | 0 | Common | Form 4 ↗ |
| Redmile Group, LLC | Director | 2025-03-31 | A | 828 | 0 | 0 | Common, indirect | Form 4 ↗ |
| M. Kathleen Behrens | Director | 2025-03-31 | A | 1,471 | 0 | 0 | Common | Form 4 ↗ |
| Steven Weber | Principal Accounting Officer | 2025-05-14 | D | 1,865 | 1 | 2,090 | Common, open-market sale | Form 4 ↗ |
| Steven Weber | Principal Accounting Officer | 2025-06-16 | D | 486 | 1 | 583 | Common, open-market sale | Form 4 ↗ |
| Lisa Lynn Decker | Chief Business Officer | 2025-06-16 | D | 951 | 1 | 1,140 | Common, open-market sale | Form 4 ↗ |
| Misbah Tahir | Chief Financial Officer | 2025-06-16 | D | 1,522 | 1 | 1,825 | Common, open-market sale | Form 4 ↗ |
| Mary Beth Harler | Director | 2025-06-16 | D | 1,522 | 1 | 1,825 | Common, open-market sale | Form 4 ↗ |
| Christina Teng Topsoe | Director | 2025-06-30 | A | 1,284 | 0 | 0 | Common | Form 4 ↗ |
| Redmile Group, LLC | Director | 2025-06-30 | A | 828 | 0 | 0 | Common, indirect | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2025-06-30 | A | 953 | 0 | 0 | Common | Form 4 ↗ |
| Michael Lee | Director | 2025-06-30 | A | 828 | 0 | 0 | Common, indirect | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2025-06-30 | A | 953 | 0 | 0 | Common | Form 4 ↗ |
| M. Kathleen Behrens | Director | 2025-06-30 | A | 1,471 | 0 | 0 | Common | Form 4 ↗ |
| Elizabeth H.Z. Thompson | Director | 2025-06-30 | A | 694 | 0 | 0 | Common | Form 4 ↗ |
| Jakob Haldor Topsoe | Director | 2025-06-30 | A | 828 | 0 | 0 | Common | Form 4 ↗ |
| Misbah Tahir | Chief Financial Officer | 2025-07-23 | D | 8,741 | 1 | 11,126 | Common, open-market sale | Form 4 ↗ |
| Mary Beth Harler | Director | 2025-07-23 | D | 14,501 | 1 | 18,457 | Common, open-market sale | Form 4 ↗ |
| Lisa Lynn Decker | Chief Business Officer | 2025-07-23 | D | 4,409 | 1 | 5,612 | Common, open-market sale | Form 4 ↗ |
| Redmile Group, LLC | Director | 2025-08-14 | D | 2,964,843 | — | — | Common | Form 4 ↗ |
| M. Kathleen Behrens | Director | 2025-08-14 | D | 22,222 | — | — | Common | Form 4 ↗ |
| William Strohl | Director | 2025-08-14 | D | 125,000 | — | — | Common | Form 4 ↗ |
| Elizabeth H.Z. Thompson | Director | 2025-08-14 | D | 7,196 | — | — | Common | Form 4 ↗ |
| M. Kathleen Behrens | Director | 2025-08-14 | D | 330,700 | — | — | Common | Form 4 ↗ |
| Mary Beth Harler | Director | 2025-08-14 | D | 323,680 | — | — | Common | Form 4 ↗ |
| Jakob Haldor Topsoe | Director | 2025-08-14 | D | 5,044,295 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jakob Haldor Topsoe | Director | 2025-08-14 | D | 91,712 | — | — | Common | Form 4 ↗ |
| Holding A/S Topsoe | Greater-than-10% holder | 2025-08-14 | D | 5,044,295 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Lee | Director | 2025-08-14 | D | 12,712 | — | — | Common | Form 4 ↗ |
| Julie Hambleton | Director | 2025-08-14 | D | 2,000 | — | — | Common | Form 4 ↗ |
| Redmile Group, LLC | Director | 2025-08-14 | D | 7,199,325 | — | — | Derivative, Class A Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | — | 2025-08-14 | D | 9,886,217 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | — | 2025-08-14 | D | 3,763,362 | — | — | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | — | 2025-08-14 | D | 357,048 | — | — | Common | Form 4 ↗ |
| M. Kathleen Behrens | Director | 2025-08-14 | D | 29,806 | — | — | Common | Form 4 ↗ |
| M. Kathleen Behrens | Director | 2025-08-14 | D | 29,807 | — | — | Common | Form 4 ↗ |
| Jakob Haldor Topsoe | Director | 2025-08-14 | D | 10,400,564 | — | — | Common | Form 4 ↗ |
| Holding A/S Topsoe | Greater-than-10% holder | 2025-08-14 | D | 10,400,564 | — | — | Common | Form 4 ↗ |
| Christina Teng Topsoe | Director | 2025-08-14 | D | 9,800 | — | — | Common | Form 4 ↗ |
| Redmile Group, LLC | Director | 2025-08-14 | D | 667,666 | — | — | Derivative, Class A Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | — | 2025-08-14 | D | 834,707 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christina Teng Topsoe | Director | 2025-08-14 | D | 5,044,295 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christina Teng Topsoe | Director | 2025-08-14 | D | 54,235 | — | — | Common | Form 4 ↗ |
| Christina Teng Topsoe | Director | 2025-08-14 | D | 10,400,564 | — | — | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (92 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Fred Schwarzer. DEF 14A, filed 2024-04-26. Section “Summary Compensation Table” · page 34. As printed: 3,207,328. View filing ↗
- Section 01, Bruce Keyt. DEF 14A, filed 2024-04-26. Section “Summary Compensation Table” · page 34. As printed: 1,571,204. View filing ↗
- Section 01, Chris Takimoto. DEF 14A, filed 2024-04-26. Section “Summary Compensation Table” · page 34. As printed: 1,562,812. View filing ↗
- Section 03, Chris Takimoto OPTION. DEF 14A, filed 2024-04-26. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Fred Schwarzer RSU. DEF 14A, filed 2024-04-26. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Fred Schwarzer OPTION. DEF 14A, filed 2024-04-26. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Chris Takimoto RSU. DEF 14A, filed 2024-04-26. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Bruce Keyt RSU. DEF 14A, filed 2024-04-26. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Bruce Keyt OPTION. DEF 14A, filed 2024-04-26. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 08, William Strohl. DEF 14A, filed 2024-04-26. Section “Director Compensation”. As printed: 236,594. View filing ↗
- Section 08, Julie Hambleton. DEF 14A, filed 2024-04-26. Section “Director Compensation”. As printed: 204,094. View filing ↗
- Section 08, Michael Loberg. DEF 14A, filed 2024-04-26. Section “Director Compensation”. As printed: 182,544. View filing ↗
- Section 08, M. Kathleen Behrens. DEF 14A, filed 2024-04-26. Section “Director Compensation”. As printed: 178,298. View filing ↗
- Section 08, Felix J. Baker. DEF 14A, filed 2024-04-26. Section “Director Compensation”. As printed: 168,549. View filing ↗
- Section 08, Elizabeth H.Z. Thompson. DEF 14A, filed 2024-04-26. Section “Director Compensation”. As printed: 167,535. View filing ↗
- Section 08, Michael Lee. DEF 14A, filed 2024-04-26. Section “Director Compensation”. As printed: 166,092. View filing ↗
- Section 08, Fred Schwarzer. DEF 14A, filed 2024-04-26. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Jakob Haldor Topsoe. DEF 14A, filed 2024-04-26. Section “Director Compensation”. As printed: —. View filing ↗
- Section 08, Christina Teng Topsoe. DEF 14A, filed 2024-04-26. Section “Director Compensation”. As printed: —. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2024-12-31. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Redmile Group, LLC 2024-12-31. Form 4, filed 2025-01-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christina Teng Topsoe 2024-12-31. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2024-12-31. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, M. Kathleen Behrens 2024-12-31. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Lee 2024-12-31. Form 4, filed 2025-01-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jakob Haldor Topsoe 2024-12-31. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth H.Z. Thompson 2024-12-31. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Weber 2025-01-15. Form 4, filed 2025-01-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Misbah Tahir 2025-03-14. Form 4, filed 2025-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lisa Lynn Decker 2025-03-14. Form 4, filed 2025-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mary Beth Harler 2025-03-14. Form 4, filed 2025-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Weber 2025-03-14. Form 4, filed 2025-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christina Teng Topsoe 2025-03-31. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jakob Haldor Topsoe 2025-03-31. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth H.Z. Thompson 2025-03-31. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Lee 2025-03-31. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2025-03-31. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2025-03-31. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Redmile Group, LLC 2025-03-31. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, M. Kathleen Behrens 2025-03-31. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Weber 2025-05-14. Form 4, filed 2025-05-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Weber 2025-06-16. Form 4, filed 2025-06-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lisa Lynn Decker 2025-06-16. Form 4, filed 2025-06-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Misbah Tahir 2025-06-16. Form 4, filed 2025-06-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mary Beth Harler 2025-06-16. Form 4, filed 2025-06-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christina Teng Topsoe 2025-06-30. Form 4, filed 2025-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Redmile Group, LLC 2025-06-30. Form 4, filed 2025-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2025-06-30. Form 4, filed 2025-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Lee 2025-06-30. Form 4, filed 2025-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2025-06-30. Form 4, filed 2025-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, M. Kathleen Behrens 2025-06-30. Form 4, filed 2025-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth H.Z. Thompson 2025-06-30. Form 4, filed 2025-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jakob Haldor Topsoe 2025-06-30. Form 4, filed 2025-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Misbah Tahir 2025-07-23. Form 4, filed 2025-07-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mary Beth Harler 2025-07-23. Form 4, filed 2025-07-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lisa Lynn Decker 2025-07-23. Form 4, filed 2025-07-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Redmile Group, LLC 2025-08-14. Form 4, filed 2025-08-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, M. Kathleen Behrens 2025-08-14. Form 4, filed 2025-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William Strohl 2025-08-14. Form 4, filed 2025-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth H.Z. Thompson 2025-08-14. Form 4, filed 2025-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, M. Kathleen Behrens 2025-08-14. Form 4, filed 2025-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mary Beth Harler 2025-08-14. Form 4, filed 2025-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jakob Haldor Topsoe 2025-08-14. Form 4, filed 2025-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jakob Haldor Topsoe 2025-08-14. Form 4, filed 2025-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Holding A/S Topsoe 2025-08-14. Form 4, filed 2025-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Lee 2025-08-14. Form 4, filed 2025-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Julie Hambleton 2025-08-14. Form 4, filed 2025-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Redmile Group, LLC 2025-08-14. Form 4, filed 2025-08-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2025-08-14. Form 4, filed 2025-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2025-08-14. Form 4, filed 2025-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2025-08-14. Form 4, filed 2025-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, M. Kathleen Behrens 2025-08-14. Form 4, filed 2025-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, M. Kathleen Behrens 2025-08-14. Form 4, filed 2025-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jakob Haldor Topsoe 2025-08-14. Form 4, filed 2025-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Holding A/S Topsoe 2025-08-14. Form 4, filed 2025-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christina Teng Topsoe 2025-08-14. Form 4, filed 2025-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Redmile Group, LLC 2025-08-14. Form 4, filed 2025-08-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2025-08-14. Form 4, filed 2025-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christina Teng Topsoe 2025-08-14. Form 4, filed 2025-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christina Teng Topsoe 2025-08-14. Form 4, filed 2025-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christina Teng Topsoe 2025-08-14. Form 4, filed 2025-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-14. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-27. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 06, 2022 vote. Form 8-K, filed 2022-06-24. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 162,785 + equity 109,107 + all other 0 = 271,892, summed across the director compensation table rows.
- Gilead Sciences, Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Gilead Sciences's own proxy. As printed: 28,437,198. View filing ↗
- Pfizer, Section 10b CEO total. DEF 14A, filed 2026-03-12. CEO total compensation as printed in Pfizer's own proxy. As printed: 27,585,301. View filing ↗
- Bristol-Myers Squibb, Section 10b CEO total. DEF 14A, filed 2026-03-25. CEO total compensation as printed in Bristol-Myers Squibb's own proxy. As printed: 21,879,919. View filing ↗
- Merck & Co., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Merck & Co.'s own proxy. As printed: 20,797,845. View filing ↗
- IGM Biosciences (subject), Section 10b CEO total. DEF 14A, filed 2024-04-26. CEO total compensation as printed in IGM Biosciences's own proxy. As printed: 3,207,328. View filing ↗